Morepen Laboratories is currently trading at Rs. 88.76, up by 0.39 points or 0.44% from its previous closing of Rs. 88.37 on the BSE.
The scrip opened at Rs. 88.90 and has touched a high and low of Rs. 91.57 and Rs. 88.55 respectively. So far 474737 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 100.80 on 10-Sep-2024 and a 52 week low of Rs. 38.56 on 13-Mar-2024.
Last one week high and low of the scrip stood at Rs. 91.57 and Rs. 84.78 respectively. The current market cap of the company is Rs. 4864.18 crore.
The promoters holding in the company stood at 35.65%, while Institutions and Non-Institutions held 3.79% and 60.56% respectively.
Morepen Laboratories’ wholly owned subsidiary -- Dr. Morepen has introduced LightLife, a 360-degree holistic weight management program designed for modern lifestyles. At its core, LightLife combines award-winning Slimbiome from the UK and Intelicaps Probiotics from Belgium - ingredients celebrated globally for their clinical efficacy in managing weight. These formulations curb cravings, promote fullness, and enhance gut health while eliminating the harmful effects often associated with extreme weight-loss tricks and fads that promise quick fixes but do more harm than good.
The program offers Pre-meal Nutrition Drinks and On-the-Go Meal, providing easy, convenient solutions that match your fast-paced lifestyle. Complemented by a state-of-the-art mobile app, LightLife enables users to access live 24x7 tracking, guided diet plans, and expert-led counselling to transform their health journey. In a world where complicated diets and all-consuming regimens are the norm, LightLife stands apart as a simple, affordable option at just Rs 599, empowering people to choose a healthy lifestyle effortlessly. Both products provide science-driven solutions, helping users stay on track without requiring constant adjustments to their daily routines
Morepen Laboratories is engaged in the manufacturing and sale of APIs/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1800.30 |
| Dr. Reddys Lab | 1275.05 |
| Cipla | 1472.05 |
| Lupin | 2098.70 |
| Zydus Lifesciences | 979.10 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
